Determination of Trans-loxoprofen-alcohol Tromethamine in Pregnant SD Rats by a Validated LC-MS/MS Method：Application to a Toxicokinetics and Tissue Distribution Study

Lingling       Xu; Wenjun       Zhou; Yanjuan       Yuan; Qing       Shao; Hongqun       Qiao

Abstract

Background: As an anti-inflammatory prodrug, loxoprofen is metabolized into transloprofenol to treat diseases related to pain and inflammation. Although loxoprofen has fewer adverse effects than other NSAIDs, the safety of its usage during pregnancy remains unclear and needs to be considered. Fortunately, the toxicokinetics and tissue distribution study of transloxoprofen- alcohol in pregnant rats can resolve the problem.

Objective: The purpose of this study is to establish a simple, sensitive, and effective LC-MS/MS analysis method for determining the concentration of trans-loxoprofen alcohol in plasma and tissues.

Methods: The analytic samples were precipitated by methanol in one step and separated using a reverse-phase Poroshell 120 EC-C18 column (4.6 mm×50 mm; 2.7 μm). And the mobile gradient phase at a flow rate of 0.6 mL/min was composed of acetonitrile and 0.1% formic acid in water. The quantitative detection was achieved by multiple-reaction monitoring mode with a positive electrospray ionization source, transitional ion pairs of m/z 265.9>184.8 for trans-loxoprofenalcohol, and 268.8>187.9 for rac-trans-loxoprofen-D3 alcohol (Internal standard).

Results: A good linearity of calibration curves for plasma and tissues was observed in the concentration range from 5.0 to 5000 ng/mL, and the lower limit of quantification was detected at 5.0 ng/mL. The intra-day and inter-day precision in plasma and tissues were within 8.94% and 7.26%, respectively. The mean extraction recovery and matrix effects in plasma and tissues were in the range of 89.08~109.27% and 89.00~106.80%, respectively. Precision of stability in plasma and tissues was within 8.91% and 7.08%, respectively.

Conclusion: Complying with the requirements of bioanalytical guidelines by validation, this method was successfully adopted to the toxicokinetics and tissue distribution study after intravenously administrated trans-loxoprofen-alcohol into pregnant SD rats.

Keywords: Trans-loxoprofen-alcohol, plasma and tissues, protein precipitation, toxicokinetics, LC-MS/MS, validation.

Graphical Abstract

[1] 
Nicholas, Moore.; Charles, P.ollack Paul, Butkerait Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther. Clin. Risk Manag.,  2015, 11, 1061-1075.
[2] 
Asami, T.; Yamanouchi, N.; Asami, A.; Tanaka, H.; Nogami, N. The effectiveness of patches containing loxoprofen sodium hydrate (lx-p) in the conservative therapy of muscular back pain—Clinical results using the japanese orthopaedic association back pain evaluation questionnaire (joabpeq). JJCRS,  2013, 4, 22-29.
[3] 
Greig, S.L.; Garnock-Jones, K.P. Loxoprofen: A review in pain and inflammation. Clin. Drug Investig.,  2016, 36(9), 771-781.
[http://dx.doi.org/10.1007/s40261-016-0440-9] [PMID:  27444038] 
[4] 
Koo, T.S.; Kim, D.H.; Ahn, S.H.; Kim, K.P.; Kim, I.W.; Seo, S.Y.; Suh, Y.G.; Kim, D.D.; Shim, C.K.; Chung, S.J. Comparison
	of pharmacokinetics of loxoprofen and its active metabolites after
	Application to a Toxicokinetics and Tissue Distribution Study Current Pharmaceutical Analysis, 2022, Vol. 18, No. 1 121
	an intravenous, intramuscular, and oral administration of loxoprofen
in rats: Evidence for extrahepatic metabolism.,  2005, 94(10), 2187-2197.
[5] 
Sakamoto, C.; Kawai, T.; Nakamura, S.; Sugioka, T.; Tabira, J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment. Pharmacol. Ther.,  2013, 37(3), 346-354.
[http://dx.doi.org/10.1111/apt.12174] [PMID:  23216412] 
[6] 
Kaniwa, N.; Ueta, M.; Nakamura, R.; Okamoto-Uchida, Y.; Sugiyama, E.; Maekawa, K.; Takahashi, Y.; Furuya, H.; Yagami, A.; Matsukura, S.; Ikezawa, Z.; Matsunaga, K.; Sotozono, C.; Aihara, M.; Kinoshita, S.; Saito, Y. Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. Allergol. Int.,  2015, 64(4), 379-381.
[http://dx.doi.org/10.1016/j.alit.2015.05.002] [PMID:  26433536] 
[7] 
Yue, Z.; Shi, J.; Jiang, P.; Sun, H. Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. Pharmacoepidemiol. Drug Saf.,  2014, 23(11), 1154-1159.
[http://dx.doi.org/10.1002/pds.3626] [PMID:  24788910] 
[8] 
Rosner, M.J.; Becker, D.P. Experimental brain injury: successful therapy with the weak base, tromethamine. With an overview of CNS acidosis. J. Neurosurg.,  1984, 60(5), 961-971.
[http://dx.doi.org/10.3171/jns.1984.60.5.0961] [PMID:  6716165] 
[9] 
Holzer, M.P.; Solomon, K.D.; Sandoval, H.P.; Vroman, D.T. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study. J. Cataract Refract. Surg.,  2002, 28(1), 93-99.
[http://dx.doi.org/10.1016/S0886-3350(01)01185-3] [PMID:  11777716] 
[10] 
Ballarín, M.; Sala, J.; Artigas, R. Review of the clinical efficacy of dexketoprofen trometamol injectable. Dolor,  2003, 18(3), 133-148.
[11] 
Siu, S.S.; Yeung, J.H.; Lao, K.T. A study on placental transfer of diclofenac in first trimester of human pregnancy. Hum. Reprod.,  2000, 15(11), 2423-2425.
[12] 
Siu, S.S.; Yeung, J.H.; Lao, K.T. An in-vivo study on placental transfer of naproxen in early human pregnancy. Hum. Reprod.,  2002, 17(4), 1056-1059.
[http://dx.doi.org/10.1093/humrep/17.4.1056] [PMID:  11925405] 
[13] 
Risser, A.; Donovan, D.; Heintzman, J.; Page, T. NSAID prescribing precautions. Am. Fam. Physician,  2009, 80(12), 1371-1378.
[PMID:  20000300] 
[14] 
Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D. Burgos-Vargas, Ruben Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 2000.
[15] 
Wan, D.; Zhao, M.; Zhang, J.; Luan, L. Development and in vitro-in vivo evaluation of a novel sustained-release loxoprofen pellet with double coating layer. Pharmaceutics,  2019, 11(6), 260.
[http://dx.doi.org/10.3390/pharmaceutics11060260] [PMID:  31195668] 
[16] 
Sawamura, R.; Kazui, M.; Kurihara, A.; Izumi, T. Absorption, distribution, metabolism and excretion of loxoprofen after dermal application of loxoprofen gel to rats. Xenobiotica,  2014, 44(11), 1026-1038.
[17] 

 Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine; CVM: Rockville, MD, 2018. 
[18] 

Detection of toxicity to reproduction for medicinal products and
toxicity to male fertility S5 (R2). Harmonised Tripartite Guideline.,, 2005.
[19] 
Lee, H.W.; Ji, H.Y.; Sohn, D.H.; Kim, S.M.; Lee, Y.B.; Lee, H.S. Liquid chromatography-tandem mass spectrometry method of loxoprofen in human plasma. Biomed. Chromatogr.,  2009, 23(7), 714-718.
[http://dx.doi.org/10.1002/bmc.1175] [PMID:  19296517] 
[20] 
Cho, H.Y.; Park, C.H.; Lee, Y.B. Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2006, 835(1-2), 27-34.
[http://dx.doi.org/10.1016/j.jchromb.2006.02.058] [PMID:  16563885] 
[21] 
Choo, K.S.; Kim, I.W.; Jung, J.K.; Suh, Y.G.; Chung, S.J.; Lee, M.H.; Shim, C.K. Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method. J. Pharm. Biomed. Anal.,  2001, 25(3-4), 639-650.
[http://dx.doi.org/10.1016/S0731-7085(00)00583-5] [PMID:  11377045] 
[22] 
Kanazawa, H.; Tsubayashi, A.; Nagata, Y.; Matsushima, Y.; Mori, C.; Kizu, J.; Higaki, M. Stereospecific Analysis of Loxoprofen in Plasma by Chiral Column Liquid Chromatography with a Circular Dichroism-Based Detector. J. Chromatogr. A,  2002, 948(1-2), 303-308.
[23] 
Dinger, J.; Meyer, M.R.; Maurer, H.H. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol. Lett.,  2014, 230(1), 28-35.
[http://dx.doi.org/10.1016/j.toxlet.2014.08.004] [PMID:  25111188] 
[24] 
Shrestha, R.; Cho, P.J.; Paudel, S.; Shrestha, A.; Kang, M.J.; Jeong, T.C.; Lee, E.S.; Lee, S. Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics,  2018, 10(3), 112.
[http://dx.doi.org/10.3390/pharmaceutics10030112] [PMID:  30072626] 
[25] 
Paudel, S.; Aarajana, S.; Cho, P.; Shrestha, R.; Kim, Y.; Lee, T.; Kim, J-H.; Jeong, T.C.; Lee, E-S.; Lee, S. Assessing drug interaction and pharmacokinetics of loxoprofen in mice treated with CYP3A modulators. Pharmaceutics,  2019, 11(9), 479.
[http://dx.doi.org/10.3390/pharmaceutics11090479] 
[26] 
Kroemer, H.K.; Klotz, U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin. Pharmacokinet.,  1992, 23(4), 292-310.
[http://dx.doi.org/10.2165/00003088-199223040-00005] [PMID:  1395362] 
[27] 
Skonberg, C.; Olsen, J.; Madsen, K.G.; Hansen, S.H.; Grillo, M.P. Metabolic activation of carboxylic acids. Expert Opin. Drug Metab. Toxicol.,  2008, 4(4), 425-438.
[http://dx.doi.org/10.1517/17425255.4.4.425] [PMID:  18433345] 
[28] 
Marin, J.J.; Briz, O.; Serrano, M.A. A review on the molecular mechanisms involved in the placental barrier for drugs. Curr. Drug Deliv.,  2004, 1(3), 275-289.
[http://dx.doi.org/10.2174/1567201043334731] [PMID:  16305390] 

Cite As